Aetna · Iort · US health-plan appeal rights

Iort denied as experimental or investigational by Aetna?

Q: How long do I have to appeal a Aetna Iort denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-05-01

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna considers IORT medically necessary for select early-stage breast cancer patients meeting TARGIT-A inclusion criteria: age ≥50, unifocal invasive ductal carcinoma, T1 (≤2cm), node-negative, hormone-receptor positive, HER2-negative, no extensive intraductal component. IORT may be delivered as single-fraction at lumpectomy (boost) or as primary partial-breast irradiation. Aetna considers IORT investigational/experimental for most non-breast indications (rectal, glioblastoma, sarcoma, recurrent rectal/pelvic) absent specific guideline support.

Source policy: Aetna CPB 0721 — Intraoperative Radiation Therapy (IORT) — read the policy

What works in the appeal

TARGIT-A 5-yr long-term (Vaidya BMJ 2020;370:m2836) — non-inferior local control vs WBRT for selected patients meeting TARGIT-A criteria, sustained at 12-yr follow-up (Vaidya 2024). ELIOT 5-yr + 10-yr (Veronesi Lancet Oncol 2013;14:1269; Orecchia 2021) — Italian electron IORT outcomes for selected low-risk profile. GEC-ESTRO consensus on partial-breast irradiation 2010/2024 update (Strnad). ASTRO APBI Consensus Statement 2017/update — IORT category eligibility table. NCCN Breast Cancer v2.2024 lists IORT as APBI option meeting selection criteria. For rectal IORT cite NCCN Rectal Cancer v3.2024 (locally advanced + R0 close margin) and Calvo et al EJC 2014 IORT outcomes. Document staging completion (sentinel node, IHC), final pathology with margins, multidisciplinary tumor board recommendation. Submit ABS / ASTRO / ASCO position statements where applicable.

The Aetna angle on Iort

## Why Aetna Denies Intraoperative Radiation Therapy as Experimental — and How to Appeal

Aetna's experimental or investigational denial for Intraoperative Radiation Therapy (IORT) means the plan has determined that IORT does not yet meet its evidentiary standard for proven clinical benefit in the specific indication requested. This is a particularly high-stakes denial because it typically cannot be resolved by simple documentation alone — it requires a substantive clinical argument that peer-reviewed evidence and professional consensus support IORT as a non-experimental standard of care for this patient's specific cancer type, stage, and clinical circumstances.

## Why This Denial Is Appealable

Aetna's experimental/investigational determination is based on its internal clinical policy review criteria, not a static regulatory standard. These criteria are subject to challenge when peer-reviewed literature and major oncology society guidelines — such as those from ASTRO, ASCO, or NCCN — support the use of IORT in the patient's precise clinical scenario. The treating oncologist is in the best position to argue that IORT is an accepted, evidence-based treatment for this indication, not an experimental one. External reviewers — who are independent oncologists — frequently disagree with payer experimental determinations when the clinical record is well-documented.

## Federal Appeal Framework

Internal appeal: File under ERISA §503 or applicable state law within the deadline on the denial letter. Request the full clinical policy Aetna used and the specific evidence standard it applied.
External review: Experimental/investigational denials are expressly covered by the ACA §2719 external-review pathway. An independent IRO staffed by qualified oncologists will review whether IORT meets the evidentiary standard for the indication. File within four months of the final internal denial.
Expedited review: If surgery is imminent or delay would compromise outcomes, request expedited external review — decisions are typically required within 72 hours.

## Documentation to Gather

Diagnosis and staging: Complete pathology, staging workup, and tumor characteristics relevant to the IORT indication.
Treating oncologist's medical-necessity letter: A detailed letter from the radiation oncologist and/or surgical oncologist explaining why IORT is a medically accepted, evidence-based treatment for this patient's specific cancer type and stage, citing peer-reviewed literature and applicable professional society guidelines.
Published guideline references: Copies of or citations to the relevant sections of ASTRO, NCCN, ASCO, or SSO guidelines that address IORT in the applicable clinical scenario.
Peer-reviewed literature: Published studies supporting IORT for the specific indication — your oncologist can identify these.
Institutional practice documentation: If IORT is a standard offering at the treating institution, documentation of that fact supports that it is not experimental in practice.

## Criteria-Mapping Structure

Obtain Aetna's IORT clinical policy and identify the specific evidentiary criteria that led to the experimental determination. For each criterion, assemble a direct counter-argument grounded in peer-reviewed evidence and guideline support. Frame the appeal as a clinical policy disagreement, not a paperwork gap — external IRO reviewers respond to the quality of the clinical argument.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other denial reasons for Aetna Iort

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.